Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...